Experimental challenge of horses after prime-boost immunization with a modified live equid alphaherpesvirus 1 vaccine administered by two different routes.
Journal
Archives of virology
ISSN: 1432-8798
Titre abrégé: Arch Virol
Pays: Austria
ID NLM: 7506870
Informations de publication
Date de publication:
04 Jan 2023
04 Jan 2023
Historique:
received:
08
06
2022
accepted:
07
09
2022
entrez:
3
1
2023
pubmed:
4
1
2023
medline:
6
1
2023
Statut:
epublish
Résumé
The immune response and protective efficacy of a modified equid alphaherpesvirus 1 (EHV-1) vaccine administered by two different routes were tested in horses. Horses that received intramuscular (IM) priming and an intranasal (IN) booster with a 28-day interval (IM-IN group [n = 6]), IN priming and IM booster (IN-IM group [n = 5]), or no vaccination (control group [n = 6]) were challenged with EHV-1 strain 10-I-224 28 days after the second vaccination. Both vaccinated groups had significantly higher serum virus-neutralizing titers than the control group, with increased levels of serum IgGa, IgGb, and IgA antibodies (p < 0.05). The nasal antibody response was dominated by the IgGa and IgGb subclasses in both vaccinated groups, with no IgA antibody response. After challenge infection, three of six control horses were pyretic for 1-4 days post-inoculation (dpi), whereas none in the vaccinated groups were pyretic during this period. The number of horses that were pyretic at 5-10 dpi was 4 out of 6 for the controls, 3 out of 6 for the IM-IN group, and 2 out of 5 for the IN-IM group. Nasal virus replication in the IN-IM group (3-4 dpi) and IM-IN group (3 dpi) was significantly lower than in the control group (p < 0.05). All of the control horses showed viremia, whereas two horses in the IM-IN group and one in the IN-IM group did not. In conclusion, although IM-IN or IN-IM vaccination did not elicit a mucosal IgA response, it provided partial protection at a level similar to that of the conventional program, likely due to systemic antibodies and mucosal IgG subclass responses.
Identifiants
pubmed: 36596958
doi: 10.1007/s00705-022-05638-w
pii: 10.1007/s00705-022-05638-w
doi:
Substances chimiques
Immunoglobulin A
0
Vaccines, Attenuated
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Patel JR, Heldens J (2005) Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)—epidemiology, disease and immunoprophylaxis: a brief review. Vet J 170:14–23
doi: 10.1016/j.tvjl.2004.04.018
Goehring LS, Wagner B, Bigbie R, Hussey SB, Rao S, Morley PS, Lunn DP (2010) Control of EHV-1 viremia and nasal shedding by commercial vaccines. Vaccine 28:5203–5211
doi: 10.1016/j.vaccine.2010.05.065
Goodman LB, Wagner B, Flaminio MJBF, Sussman KH, Metzger SM, Holland R, Osterrieder N (2006) Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24:3636–3645
doi: 10.1016/j.vaccine.2006.01.062
Heldens JGM, Hannant D, Cullinane AA, Prendergast MJ, Mumford JA, Nelly M, Kydd JH, Weststrate MW, van den Hoven R (2001) Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV
doi: 10.1016/S0264-410X(01)00131-1
Bannai H, Tsujimura K, Kondo T, Nemoto M, Yamanaka T, Sugiura T, Maeda K, Matsumura T (2011) Induction of a Th-1-biased IgG subclass response against equine herpesvirus type 1 in horses previously infected with type 4 virus. J Vet Med Sci 73:535–539
doi: 10.1292/jvms.10-0456
Breathnach CC, Yeargan MR, Sheoran AS, Allen GP (2001) The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet J 33:651–657
doi: 10.2746/042516401776249318
Patel JR, Bateman H, Williams J, Didlick S (2003) Derivation and characterisation of a live equid herpes virus-1 (EHV-1) vaccine to protect against abortion and respiratory disease due to EHV-1. Vet Microbiol 91:23–39
doi: 10.1016/S0378-1135(02)00259-6
Patel JR, Földi J, Bateman H, Williams J, Didlick S, Stark R (2003) Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Vet Microbiol 92:1–17
doi: 10.1016/S0378-1135(02)00358-9
Patel JR, Didlick S, Bateman H (2004) Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection. Equine Vet J 36:447–451
doi: 10.2746/0425164044868332
Slater JD, Gibson JS, Field HJ (1993) Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. J Gen Virol 74:819–828
doi: 10.1099/0022-1317-74-5-819
Tewari D, Gibson JS, Slater JD, O’Neill T, Hannant D, Allen GP, Field HJ (1993) Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1. Arch Virol 132:101–120
doi: 10.1007/BF01309846
Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kokado H, Kondo T, Matsumura T (2018) Comparison of protective efficacies between intranasal and intramuscular vaccination of horses with a modified live equine herpesvirus type-1 vaccine. Vet Microbiol 222:18–24
doi: 10.1016/j.vetmic.2018.06.015
Schnabel CL, Wimer CL, Perkins G, Babasyan S, Freer H, Watts C, Rollins A, Osterrieder N, Wagner B (2018) Deletion of the ORF2 of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity. BMC Vet Res 14:245
doi: 10.1186/s12917-018-1563-4
Schnabel CL, Babasyan S, Rollins A, Freer H, Wimer CL, Perkins GA, Raza F, Osterrieder N, Wagner B (2019) An equine herpesvirus type 1 (EHV-1) Ab4 open reading frame 2 deletion mutant provides immunity and protection from EHV-1 infection and disease. J Virol 93:e01011-e1019
doi: 10.1128/JVI.01011-19
Lapuente D, Fuchs J, Willar J, Antao AV, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pohlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Uberla K, Tenbusch M (2021) Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun 12:6871
doi: 10.1038/s41467-021-27063-4
Mantis NJ, Kozlowski PA, Mielcarz DW, Weissenhorn W, Neutra MR (2001) Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19:3990–4001
doi: 10.1016/S0264-410X(01)00115-3
Yuan L, Azevedo MSP, Gonzalez AM, Jeong K, Nguyen TV, Lewis P, Iosef C, Herrmann JE, Saif L (2005) Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model. Vaccine 23:3925–3936
doi: 10.1016/j.vaccine.2005.03.009
Crouch CF, Daly J, Henley W, Hannant D, Wilkins J, Francis MJ (2005) The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Vet Immunol Immunopathol 108:345–355
doi: 10.1016/j.vetimm.2005.06.009
Hannant D, Easeman R, Mumford JA (1998) Equine mucosal immune system: Intranasal vaccination with inactivated equine influenza virus protects from infection. In: Wernery U, Wade JF, Mumford JA, Kaaden OR (eds) Equine infectious diseases VIII. R&W Publications, Newmarket, pp 50–56
Matsumura T, Sugiura T, Imagawa H, Fukunaga Y, Kamada M (1992) Epizootiological aspects of type 1 and type 4 equine herpesvirus infections among horse populations. J Vet Med Sci 54:207–211
doi: 10.1292/jvms.54.207
Kawakami Y, Nakano K, Kume T, Hiramune T, Murase N (1970) Abortion by equine rhinopneumonitis virus in Hidaka, Hokkaido district in Japan. Bull Natl Inst Anim Health 61:9–16 (in Japanese)
Andoh K, Takasugi M, Mahmoud HYAH, Hattori S, Terada Y, Noguchi K, Shimoda H, Bannai H, Tsujimura K, Matsumura T, Kondo T, Maeda K (2013) Identification of a major immunogenic region of equine herpesvirus-1 glycoprotein E and its application to enzyme-linked immunosorbent assay. Vet Microbiol 164:18–26
doi: 10.1016/j.vetmic.2013.01.033
Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Maeda K, Kondo T (2016) Improvement of an enzyme-linked immunosorbent assay for equine herpesvirus type 4 by using a synthetic-peptide 24-mer repeat sequence of glycoprotein G as an antigen. J Vet Med Sci 78:309–311
doi: 10.1292/jvms.15-0275
Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T (2013) Development of a focus-reduction neutralizing test for detecting equine herpesvirus type-1-neutralizing antibodies. J Vet Med Sci 75:1209–1212
doi: 10.1292/jvms.13-0043
Bannai H, Tsujimura K, Nemoto M, Ohta M, Yamanaka T, Kokado H, Matsumura T (2019) Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine. BMC Vet Res 15:280
doi: 10.1186/s12917-019-2036-0